Vimarsana
Biggest News Aggregation in the World

Page 2 - Third Bridge News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Third Bridge. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Third Bridge Today - Breaking & Trending Today

Cisco forecasts fourth-quarter revenue above estimates on enterprise demand, ET Telecom - Vimarsana News

Cisco forecasts fourth-quarter revenue above estimates on enterprise demand, ET Telecom

In recent quarters, Cisco has benefited from an increase in spending, with companies trying to boost their growing artificial intelligence and cloud computing needs.

Cisco targets revenue of $13.6 bn during current quarter - Vimarsana News

Cisco targets revenue of $13.6 bn during current quarter

Cisco revealed its financial result, saying its revenue fell 13 percent to $12.7 billion with net income of $1.9 billion for third quarter

Explained: Why Tesla CEO Elon Musk wants to buy Twitter and all other details – Rashtra News - Vimarsana News

Explained: Why Tesla CEO Elon Musk wants to buy Twitter and all other details – Rashtra News

Explained: Why Tesla CEO Elon Musk wants to buy Twitter and all other details - Rashtra News : Rashtra News #Explained #Tesla #CEO #Elon #Musk #buy #Twitter #details #Times #India Tesla CEO Elon Musk now says he wants to buy Twitter outright, taking it private to restore its commitment to what he terms "free speech."

Amgen investors await weight-loss drug data - Vimarsana News

Amgen investors await weight-loss drug data

Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.

Source: yahoo.com
Amgen investors await weight-loss drug data - Vimarsana News

Amgen investors await weight-loss drug data

By Deena Beasley (Reuters) - Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly ...

Source: wsau.com